Skin conditions (dermatitis, eczema, psoriasis) Board decisions

The Board denied the Veteran's claim for a compensable rating for neurodermatitis as the evidence did not support that the disability affected more than 5 percent of his body or required intermittent systemic therapy.

The Board denied increased ratings for the Veteran's forehead and left forearm scars, as well as psoriasis, and also denied earlier effective dates for service connection of these conditions.

The Veteran was granted a total disability rating based on individual unemployability from April 4, 2009, to July 9, 2015.

The Board denied service connection for a psychiatric disability, as the weight of evidence supported that it had its onset during a period of service adjudicated dishonorable for VA purposes and there was no continuity of symptomatology to the present.

The appeal for service connection for asthma and pseudo folliculitis barbae (PFB) was dismissed due to the Veteran's concurrent election of review options.

The Board granted readjudication of the claim for service connection for PTSD, denied service connection for an acquired psychiatric condition claimed as PTSD, dismissed the claim for chronic sinusitis, and denied increased ratings for various scars and conditions.

The Board denied the veteran's claims for earlier effective dates and initial compensable ratings for tinea pedis, onychomycosis, and lumbosacral strain with degenerative arthritis.

The Veteran's effective date for service connection of PTSD is granted as May 29, 2006, but no earlier. The claims for service connection for digestive disorder, eating disorder, acne, facial scars, and depression are remanded.

The Board denied increased ratings for postural vertigo, lumbosacral strain with DDD and degenerative changes, eczematous dermatitis of the hands and intermittent axillary eruption, and service connection for bilateral plantar fasciitis.

The Board denied the Veteran's appeal for an earlier effective date for service connection for dermatitis, finding that November 15, 2022, was the correct effective date.

The Veteran withdrew all claims in this appeal, and the Board has dismissed the appeals.

The veteran withdrew the appeal regarding all claims for service connection, and the Board dismissed these claims.

The Board granted service connection for dermatitis, chronic fatigue syndrome, left knee disorder, left ankle disorder, and lumbar spine disorder. The initial ratings for right knee patellofemoral pain syndrome and shin splints of the left lower extremity were denied.

The Board granted the restoration of a 60 percent rating for spongiotic dermatitis, effective June 5, 2025, as the reduction was improper.

The Board granted service connection for pseudofolliculitis and bilateral lower extremity peripheral neuropathy, but denied increased ratings for the Veteran's foot, cervical spine, lumbosacral spine, psychiatric disorder, and other conditions.

The Board granted a 10 percent disability rating for ocular rosacea but denied an earlier effective date and a compensable rating for acne rosacea.

The Board granted service connection for bilateral tinnitus with an effective date of January 4, 2022, but no earlier. Service connection was also granted for an acquired psychiatric disorder to include depression and posttraumatic stress disorder (PTSD).

The Board denied the veteran's claims for increased ratings for pseudofolliculitis barbae, right hand and wrist scars, and right wrist fracture residuals with tendinitis. The claims for a compensable rating for right small finger fracture residuals and higher than 10 percent rating for right wrist fracture residuals were remanded.

The Board granted a 50 percent rating for limitation of extension of the left knee, subject to the amputation rule, and denied all other claims.

The Board denied service connection for a skin disability, claimed as chloracne, due to the lack of evidence showing a current diagnosis and no in-service incurrence or aggravation. The claims for right lower extremity (RLE) and left lower extremity (LLE) diabetic peripheral neuropathy were remanded for further development.